EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Predictors of Developing Hepatocellular Carcinoma in Treated HCV-Carriers in Morocco according to University Hospital Experience

Younès Cherradi, Rajaa Afifi, Hanaa Benbrahim, Wafaa Essamri, Imane Benelbarhdadi, Fatima Zahra Ajana, Hadj Omar El Malki, Mustapha Benazzouz, Abdellah Essaid

ISRN Hepatology · 2013

DOI: 10.1155/2013/438306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Hepatology, 2013. Verfasst von Younès Cherradi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatogastroenterology (Medicine C), Ibn Sina Hospital, Rabat, Morocco. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatitis C is the first major cause for HCC in Morocco. Antiviral treatment reduces the risk of developing HCC but few cases of HCC in HCV-treated patients were reported. We aimed to define this population’s features and to identify predictive factors of developing HCC. Patients and Methods . We included all HCV carriers who developed HCC after antiviral treatment from January 2002 to April 2010. We compare HCV-treated patients with no developed HCC to HCC population using khi-2 and Fisher Exact analysis.

Results

369 HVC-treated patients were considered, and 20 HCC were reported. The risk of HCC was not significant according to gender and genotypes (resp., P = 0.63 and P = 0.87 ). Advanced age and severe fibrosis were significant risk factors (resp., P = 0.003 and P = 0.0001 ). HCC was reported in 2.6% of sustained virological responders versus 12.5% of nonresponders ( P = 0.004 ).

Conclusion

In our series, 5% of previously treated patients developed an HCC. Advanced age and severe fibrosis at HCV diagnosis are predictive factors of HCC occurrence. Sustained virological response reduces considerably the risk of HCC occurrence but screening is indicated even after SVR.

Autor:innen und Institutionen

  • Department of Hepatogastroenterology (Medicine C), Ibn Sina Hospital, Rabat, Morocco.
  • Biostatical, Clinical Research and Epidemiological Laboratory (LBRCE), Medical School, University Mohammed Vth Souissi, Rabat, Morocco.

Zitieren

APA

Cherradi, Y., Afifi, R., Benbrahim, H., Essamri, W., Benelbarhdadi, I., Ajana, F. Z., El Malki, H. O., Benazzouz, M., & Essaid, A. (2013). Predictors of Developing Hepatocellular Carcinoma in Treated HCV-Carriers in Morocco according to University Hospital Experience. ISRN Hepatology. https://doi.org/10.1155/2013/438306

Vancouver

Cherradi Y, Afifi R, Benbrahim H, Essamri W, Benelbarhdadi I, Ajana FZ, et al. Predictors of Developing Hepatocellular Carcinoma in Treated HCV-Carriers in Morocco according to University Hospital Experience. ISRN Hepatology. 2013. doi:10.1155/2013/438306

BibTeX
@article{Cherradi2013,
  author = {Cherradi, Younès and Afifi, Rajaa and Benbrahim, Hanaa and Essamri, Wafaa and Benelbarhdadi, Imane and Ajana, Fatima Zahra and El Malki, Hadj Omar and Benazzouz, Mustapha and Essaid, Abdellah},
  title = {Predictors of Developing Hepatocellular Carcinoma in Treated HCV-Carriers in Morocco according to University Hospital Experience},
  journal = {ISRN Hepatology},
  year = {2013},
  doi = {10.1155/2013/438306}
}
Kostenlos starten →